DHODH and colorectal carcinoma: Importantly, these cells are known to be highly resistant to 5-FU (Bracht et al., 2010), the backbone chemotherapeutic used in CRC, revealing that inhibition of DHODH can exert therapeutic benefit despite cellular resistance to an anti-metabolite that targets the pyrimidine pathway.